Characterization of Immunological Profile of Renal Transplant Patients Undergoing Induction Treatment With Thymoglobulin vs. IL-2 Receptor Antagonist Basiliximab

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00842699

Enrollment

Registered

2009-02-12

Start date

2008-09-30

Completion date

2011-03-31

Last updated

2011-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Transplantation

Brief summary

The goal of the study is to find out the effects of two different drugs used at the beginning of organ transplantation on different populations of immune cells in the body of patients.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* all patients considered for transplantation

Exclusion criteria

* none

Design outcomes

Primary

Measure	Time frame
The primary outcome is to look for expansion of regulatory T cells at one year.	12 months

Countries

United States

Outcome results